Original Study

Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years

Ashkan Mortezavi,¹ Tullio Sulser,¹ Jacopo Robbiani,¹ Eva Drescher,¹ Daniel Disteldorf,¹ Daniel Eberli,¹ Cedric Poyet,¹ Martin K. Baumgartner,¹ Hans-Helge Seifert,^{1,2} Thomas Hermanns¹

Abstract

The long-term oncologic outcomes for laparoscopic radical prostatectomy (LRP), a minimal invasive approach for the treatment of localized prostate cancer, are still only sparsely available. We, therefore, evaluated the outcomes after 10 years of an initial series of 100 patients who had undergone LRP. The estimated 10-year biochemical recurrence-free survival was 78.6%, indicating excellent long-term oncologic control for patients with localized prostate cancer.

Introduction: When laparoscopic radical prostatectomy (LRP) was introduced as a novel treatment option for prostate cancer, it had to compete with the established open techniques. The short- and intermediate-term oncologic and functional outcomes were encouraging and comparable to those with retropubic radical prostatectomy. However, the long-term oncologic safety for LRP has yet to be fully elucidated. We evaluated the long-term oncologic outcomes of an initial series of patients who had undergone LRP. Patients and Methods: An initial unselected and consecutive series of 100 patients who had undergone LRP for clinically localized prostate cancer from 1999 to 2001 was identified. The pre-, intra-, and postoperative data were collected. Biochemical recurrence (BCR) was defined as a prostate-specific antigen (PSA) value of ≥ 0.2 ng/mL. The outcome measures were cancer control (CC), BCR-free survival (BCRFS), cancer-specific survival (CSS), and overall survival (OS). Results: The mean patient age was 64 \pm 7 years, and the mean preoperative PSA level was 9.6 \pm 8.3 ng/mL. Of the 100 patients, 79 (79%) had stage pT2 and 15 (15%) had stage pT3 disease. Positive surgical margins were found in 25 patients (25%; 16.4% for pT2 and 40% for pT3). The median follow-up time was 126 months (range, 60-176 months). The 5-year CC rate was 82%. The estimated 10-year BCRFS was 83% and 80% for patients with stage pT2 and pT3 tumors, respectively. The median time to BCR was 52 months (range, 6-144 months). The estimated 10-year CSS and OS was 98% and 93%, respectively. Conclusion: Our long-term follow-up data from an initial unselected patient cohort have indicated that LRP offers excellent long-term oncologic control for patients with localized prostate cancer.

Clinical Genitourinary Cancer, Vol. ■, No. ■, ■-■ © 2015 Elsevier Inc. All rights reserved.

Keywords: Biochemical recurrence, Cancer-specific survival, Minimally invasive, Overall survival, Positive surgical margin rate

Introduction

Laparoscopic radical prostatectomy (LRP) for the treatment of clinically localized prostate cancer (PCa) was introduced in 1997 by

Schuessler et al. The lower intra- and perioperative morbidity compared with the reference standard technique of open retropubic radical prostatectomy (RRP) was one proposed advantage of the

H.-H.S. and T.H. contributed equally.

Submitted: Jul 27, 2015; Revised: Oct 22, 2015; Accepted: Nov 11, 2015

Address for correspondence: Thomas Hermanns, MD, Department of Urology, University Hospital Zurich, Frauenklinikstrasse10, Zürich 8091, Switzerland E-mail contact: thomas.hermanns@usz.ch

¹Department of Urology, University Hospital Zürich, University of Zurich, Zurich, Switzerland

²Department of Urology, University Hospital Basel, Basel, Switzerland

Long-Term Oncologic Outcomes for LRP of PCa

Characteristic Value Preoperative data Age (years) 63.5 ± 6.5 Body mass index (kg/m²) 26.5 ± 3.1 Preoperative PSA (ng/mL) Mean 9.6 ± 8.3 <10 69 (69) ≥ 10 Clinical stage T1 53 (63) T2 45 (45) T3 2 (2) Biopsy Gleason score 69 (69) 7 23 (23) 8-10 8 (8) Risk group³ Low 47 (47) 47 (47) 11	Table 1 Patient Characteristics	s (n = 100)
Age (years) 63.5 ± 6.5 Body mass index (kg/m²) 26.5 ± 3.1 Preoperative PSA (ng/mL) Mean 9.6 ± 8.3 <10 69 (69) ≥10 31 (31) Clinical stage T1 53 (53) T2 45 (45) T3 2 (2) Biopsy Gleason score 5-6 69 (69) 7 23 (23) 8-10 8 (8) Risk group³ Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)	Characteristic	Value
Body mass index (kg/m²) 26.5 ± 3.1 Preoperative PSA (ng/mL) Mean 9.6 ± 8.3 <10	Preoperative data	
Preoperative PSA (ng/mL) Mean 9.6 ± 8.3 <10	Age (years)	63.5 ± 6.5
Preoperative PSA (ng/mL) Mean 9.6 ± 8.3 <10		26.5 ± 3.1
Mean 9.6 ± 8.3 <10		
≥10 Clinical stage T1 53 (53) T2 45 (45) T3 2 (2) Biopsy Gleason score 5-6 6 (69 (69) 7 (23 (23) 8-10 8 (8) Risk group³ Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) Positive margin status pT2a-T2c pT3a-T3b pT4 Localization of margin Apex Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c pT3a-T3b pT4 G (6) Gleason score 4-6 Gleason score 4-6 54 (54)		9.6 ± 8.3
≥10	<10	69 (69)
Clinical stage T1 53 (53) T2 45 (45) T3 2 (2) Biopsy Gleason score 69 (69) 7 23 (23) 8-10 8 (8) Risk group ^a Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy 17 (17) Neoadjuvant hormone deprivation therapy 5 (5) theretapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status p72a-T2c 13 (16) p73a-T3b 6 (40) p74 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) p7 stage p72a-T2c 79 (79) p73a-T3b 15 (15) p74 6 (6) Gleason score 4-6 54 (54)	>10	
T1 53 (53) T2 45 (45) T3 2 (2) Biopsy Gleason score 5-6 69 (69) 7 23 (23) 8-10 8 (8) Risk group³ Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)	Clinical stage	,
T2		53 (53)
T3 2 (2) Biopsy Gleason score 5-6 69 (69) 7 23 (23) 8-10 8 (8) Risk group ^a Low 47 (47) Intermediate 36 (36) 41 (17) Neoadjuvant hormone deprivation therapy 5 (5) Intraoperative data 292 ± 101 Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status 5 (40) pT4 6 (40) pT4 6 (100) Localization of margin 4 (46) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) <	T2	
Biopsy Gleason score 5-6 69 (69) 7 23 (23) 8-10 8 (8) Risk group ^a Low 47 (47) Intermediate 36 (36) 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
5-6 69 (69) 7 23 (23) 8-10 8 (8) Risk group ⁶ 47 (47) Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy 5 (5) Intraoperative data 292 ± 101 Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results 70 (20) Prostate weight (g) 54 ± 19 Positive margin status 54 (40) pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		_ (-)
7 23 (23) 8-10 8 (8) Risk group³ Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		69 (69)
Risk group ^a		
Risk groupa Low	·	
Low 47 (47) Intermediate 36 (36) High 17 (17) Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)	0.10	J (0)
Intermediate		47 (47)
High Neoadjuvant hormone deprivation therapy Intraoperative data Operative time (min) Estimated blood loss (mL) Lymph node dissection None None None None None None Sa (38) One side 42 (42) Both sides Conversion Pathologic results Prostate weight (g) Positive margin status pT2a-T2c pT3a-T3b Apex Apex Dorsal/lateral Apex Dorsal/lateral Basis pT2a-T2c pT stage pT2a-T2c pT stage pT2a-T3b pT3a-T3b f (40) Basis f (20) Multiple 2 (2) pT stage pT2a-T2c pT3a-T3b f (6) Gleason score 4-6 54 (54)		, .
Neoadjuvant hormone deprivation therapy 5 (5) Intraoperative data 292 ± 101 Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure None None side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results 54 ± 19 Positive margin status 54 ± 19 Positive margin status 6 (40) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 4 (16) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
Intraoperative data 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure 38 (38) None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status 13 (16) pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)	Neoadjuvant hormone deprivation	, ,
Operative time (min) 292 ± 101 Estimated blood loss (mL) 674 ± 563 Lymph node dissection 39 (39) Nerve-sparing procedure 38 (38) None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Frostate weight (g) Positive margin status 54 ± 19 positive margin status 6 (40) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
Estimated blood loss (mL) Lymph node dissection None None None Sa (38) One side 42 (42) Both sides 20 (20) Conversion Pathologic results Prostate weight (g) Positive margin status pT2a-T2c pT3a-T3b Apex Apex Apex Dorsal/lateral Apex Dorsal/lateral Basis 5 (20) Multiple pT2a-T2c pT3a-T3b fo (40) pT4 Cocalization of margin Apex 24 (56) Dorsal/lateral Apex		202 ± 101
Lymph node dissection 39 (39) Nerve-sparing procedure 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		
Nerve-sparing procedure None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status 13 (16) pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		
None 38 (38) One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results		39 (39)
One side 42 (42) Both sides 20 (20) Conversion 4 (4) Pathologic results 54 ± 19 Prostate weight (g) 54 ± 19 Positive margin status 13 (16) pT3a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		20 (20)
Both sides 20 (20) Conversion 4 (4) Pathologic results Prostate weight (g) 54 ± 19 Positive margin status pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
Conversion 4 (4) Pathologic results 54 ± 19 Prostate weight (g) 54 ± 19 Positive margin status 13 (16) pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6	0110 0100	` '
Pathologic results 54 ± 19 Positive margin status 54 ± 19 pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 4-6 54 (54)		
Prostate weight (g) 54 ± 19 Positive margin status 13 (16) pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		4 (4)
Positive margin status pT2a-T2c		54 + 40
pT2a-T2c 13 (16) pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		54 ± 19
pT3a-T3b 6 (40) pT4 6 (100) Localization of margin 24 (56) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6		10 (10)
pT4 6 (100) Localization of margin 24 (56) Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 54 (54)	·	
Localization of margin Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 54 (54)	·	
Apex 24 (56) Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 54 (54)	·	6 (100)
Dorsal/lateral 4 (16) Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 4-6 54 (54)		04 /50
Basis 5 (20) Multiple 2 (2) pT stage 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 54 (54)	·	
Multiple 2 (2) pT stage 79 (79) pT3a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 54 (54)		
pT stage pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
pT2a-T2c 79 (79) pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		2 (2)
pT3a-T3b 15 (15) pT4 6 (6) Gleason score 4-6 54 (54)		
pT4 6 (6) Gleason score 4-6 54 (54)		
Gleason score 4-6 54 (54)	·	
4-6 54 (54)	·	6 (6)
· ,		
7 32 (32)	4-6	54 (54)
- I and the second of the seco	7	32 (32)

Table 1 Continued	
Characteristic	Value
8-10	14 (14)
Lymph node yield	10 ± 4
Positive nodal status	5 (5)

Data presented as mean \pm standard deviation or n (%) Abbreviation: PSA = prostate-specific antigen. ^aD'Amico classification ¹⁶

novel minimally invasive technique. However, to become a true alternative for the treatment of clinically localized PCa, the non-inferiority of LRP compared with RRP in terms of functional and oncologic outcomes also had to be shown.

The initial reports were encouraging and revealed lower perioperative morbidity for the minimally invasive approach.²⁻⁵ The postoperative urinary incontinence and erectile dysfunction rates were comparable to those reported from large case series of RRP.^{2,5-7} The initial data regarding the oncologic safety of LRP were limited to the positive surgical margin (PSM) rates as a predictor of tumor recurrence. Several groups reported PSM rates after LRP, comparable to those reported for RRP.⁶⁻⁸ Subsequently, the short- to mid-term oncologic outcomes, including biochemical recurrence-free survival (BCRFS), cancer-specific survival (CSS), and overall survival (OS), were reported from larger cohorts.⁹⁻¹⁵ The promising initial results led to the acceptance of LRP as a suitable treatment option for localized PCa. However, the true long-term oncologic safety of LRP is yet to be fully elucidated.

The aim of the present investigation was to analyze long-term oncologic outcomes of an initial unselected and consecutive series of patients who had undergone LRP for clinically localized PCa.

Patients and Methods

The initial 100 patients who had undergone LRP for clinically localized PCa from 1999 to 2001 at our tertiary care academic center (University Hospital Zürich) were retrospectively identified. Before 1999, RRP was the standard surgical treatment option offered to patients with localized PCa at our institution. In 1999, LRP became the standard procedure in our center, and no patient underwent open RRP during the study period. Thus, the patient cohort in the present investigation represents a true consecutive and unselected patient series. The electronic hospital medical records were reviewed to collect the pre-, intra-, and postoperative data. The referring urologists or the patients' general practitioners were interviewed for follow-up information if the follow-up examinations were not performed at our center. The local ethics committee approved the present study.

LRP was performed by a single surgeon (T.S.) using the transperitoneal technique described by Guillonneau and Vallancien⁴ in 2000. Bilateral pelvic lymph node dissection was performed in patients with intermediate- or high-risk PCa. Preoperative risk

Download English Version:

https://daneshyari.com/en/article/5581269

Download Persian Version:

https://daneshyari.com/article/5581269

<u>Daneshyari.com</u>